Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial

Journal:

Nature Communications

Published:

2025-08-18

DOI:

10.1038/s41467-025-63031-y

Affiliations:

17

Authors:

43

Go to article

Institutions	Authors	Share
Denali Therapeutics, United States of America (USA)	32.000000 32.000000 32.000000 32.000000	0.74
Centre for Human Drug Research (CHDR), Netherlands	3.000000	0.07
The University of Queensland (UQ), Australia	2.500000	0.06
University Medical Center Utrecht (UMC Utrecht), Netherlands	2.000000	0.05
University of California, San Diego (UC San Diego), United States of America (USA)	1.750000	0.04
Leiden University Medical Center (LUMC), Netherlands	1.000000	0.02
The University of Sydney (USYD), Australia	0.500000	0.01
Sanford Laboratories for Innovative Medicines, United States of America (USA)	0.250000	0.01

Interested in Neurosciences?